Autism

SciSparc Signs Non-Binding Letter of Intent for Exclusive Global Out-Licensing of Pain Treatment for Approximately $6 million

SciSparc will receive additional payments and execution fees if certain milestones are met TEL AVIV, Israel, July 17, 2024 (GLOBE…

4 months ago

STALICLA appoints Dr. Purnanand Sarma, PhD, as Chair of the Board of Directors

Sarma1 2 Dr. Purnanand Sarma, PhD Press Release Dr. Sarma brings exceptional expertise in all facets of the pharmaceutical and…

5 months ago

SciSparc Signs Non-Binding Letter of Intent for Spin Off of Advanced Clinical Stage Pharmaceutical Portfolio to Publicly Traded Company

According to the agreement, SciSparc’s pharmaceuticals assets are valued at approximately $11.6 million TEL AVIV, Israel, July 08, 2024 (GLOBE…

5 months ago

Transforming Children’s Lives: DP World’s Aviv Clinics Dubai’s Revolutionary Youth Protocol

DUBAI, United Arab Emirates, July 07, 2024 (GLOBE NEWSWIRE) -- At DP World's Aviv Clinics Dubai, the world’s most advanced…

5 months ago

STALICLA publishes pioneering phase 1b data on precision treatment for autism spectrum disorder in Biomedicines

Press Release STALICLA’s precision psychiatry study highlights strong EEG-based target engagement of STP1 treatment in defined subgroup of patients with…

5 months ago

Action Behavior Centers Establishes the Action Institute for Outcomes Research Led by Dr. Linda LeBlanc

AUSTIN, TX / ACCESSWIRE / June 21, 2024 / Action Behavior Centers is thrilled to announce the establishment of the…

5 months ago

Clene Presents Preliminary Data for CNM-Au8® as a Potential Treatment for Rett Syndrome

CNM-Au8 demonstrated neuroprotective effects in an in vitro model of Rett Syndrome, a rare pediatric neurodevelopmental diseaseCNM-Au8 also demonstrated rescue…

5 months ago

Christopher Barnett, Founder & CEO of ABA Centers, Named Entrepreneur Of The Year 2024 Florida Winner by EY

FORT LAUDERDALE, Fla., June 17, 2024 /PRNewswire/ -- This weekend, Ernst & Young LLP (EY US) named Christopher Barnett, Founder &…

5 months ago

AscellaHealth Chairman and President Bill Oldham Named 2024 Philadelphia Titan 100

BERWYN, Pa.--(BUSINESS WIRE)--Titan CEO and headline sponsor Wipfli LLP are pleased to announce Bill Oldham, chairman and president, AscellaHealth, as a…

5 months ago

Spinogenix Announces U.S. FDA Orphan Drug Designation Granted to SPG601 for the Treatment of Fragile X Syndrome

Receiving Orphan Drug Designation for SPG601 emphasizes the pressing demand for novel therapies for individuals living with Fragile X SyndromeSAN…

6 months ago